Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris

Journal of Dermatological Treatment

Volumn 16, Issue 4, 2005, Pages 234-237

  Vali, Anahita ^a,d   Asilian, Ali ^a   Khalesi, Elaheh ^b   Khoddami, Leila ^b   Shahtalebi, Mohammadali ^a   Mohammady, Maryam ^c  

^a Department of Dermatology ^*  (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TORONTO   (Canada)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Caffeine; Cyclic adenosine monophosphate (cAMP); Psoriasis; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CIPAMFYLLINE; CYCLIC AMP; METHYLXANTHINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; EVALUATION; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADMINISTRATION, TOPICAL; ADULT; CAFFEINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PSORIASIS; TREATMENT OUTCOME;

EID: 27744471577     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630510011801     Document Type: Article

References (11)

1. Christopher E. Psoriasis: epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20.
2. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Ebling FJG, et al., editors. Textbook of dermatology, 6th edn, vol. 2. Oxford: Blackwell Scientific Publications, 1998;1589-614.
3. Hoffman BB. Catecholamine, sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman Goodman A, editors. The pharmacological basis of therapeutics, 10th edn. New York: McGraw-Hill, 2001; 253-5.
4. Boushey HA. Bronchodilators and other agents used in asthma. In: Katzung BG, editor. Basic and clinical pharmacology, 7th edn. Los Altos, CA: Appleton & Lange, 1998; 330-7.
5. Petrazzuoli M, Goldsmith LA. Molecular mechanisms of cell signaling. In: Freedberg IM, Eisen AZ, Wolf K, et al., editors. Fitzpatrick's dermatology in general medicine, 5th edn. New York: McGraw Hill, 1999;120-3.
6. Elias PM, Jackson SM. What does normal skin do? In: Ardnt KA, LeBoit PE, Robinson JK, et al., editors. Cutaneous medicine and surgery, 1st edn, vol. 100. Philadelphia: WB Saunders, 1996;46-50.
7. Griffiths CEM, Van Leent EJ, Gilbert M, Traulsen J, Cipamfylline Study Group, Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol. 2002;147:299-307.
8. Fleming KA. The skin. In: McGee JO, Isaacson PG, Wright NA, editors. Oxford textbook of pathology, 1st edn, vol. 2b. Oxford: Oxford University Press, 1992;7146.
9. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, Alefacept Clinical Study Group, An international, randomized, double-blind, placebo controlled phase 3 trial of intramuscular Alfacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-27.
10. Koretzkey GA, Peterson EJ. T-cell activation and inactivation. In: Clinical immunology: principles and practice, 2nd edn, vol. 1. St Louis: Mosby, 2001;10.1-10.2.
11. Rodwell VW. Nucleotides. In: Murray RK, Granner DK, Mayes PA, et al., editors. Harper's biochemistry, 23rd edn. Stamford, CT: Appleton & Lange, 1993; 256.